CIC
FATE icon

Cornercap Investment Counsel’s Fate Therapeutics FATE Stock Holding History

Cornercap Investment Counsel’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-20,683
Closed -$72.4K – 492
2024
Q3 		$72.4K Sell
20,683
-22,789
-52% -$88.7K 0.02% 496
2024
Q2 		$143K Sell
43,472
-340
-0.8% -$1.49K 0.02% 560
2024
Q1 		$322K Buy
43,812
+2,475
+6% +$15.3K 0.05% 511
2023
Q4 		$155K Hold
41,337
– – 0.03% 546
2023
Q3 		$87.6K Sell
41,337
-526
-1% -$1.74K 0.02% 539
2023
Q2 		$199K Hold
41,863
– – 0.03% 515
2023
Q1 		$239K Buy
+41,863
New +$253K 0.04% 484

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Cornercap Investment Counsel's FATE Position: Q4 2024 in Review

Cornercap Investment Counsel sold out of Fate Therapeutics (FATE) in Q4 2024, closing a stake of 20,683 shares — an estimated $72.4K sold.

Cornercap Investment Counsel first reported a position in FATE in Q1 2023 and held it in 7 quarters. The position peaked at $322K in Q1 2024. 159 funds tracked by Wall St. Rank hold FATE as of Q4 2024.

  • Cornercap Investment Counsel reported no remaining Fate Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Cornercap Investment Counsel sold 20,683 Fate Therapeutics shares in Q4 2024, an estimated $72.4K.
  • Cornercap Investment Counsel first reported a position in Fate Therapeutics in Q1 2023 and held it in 7 quarters.
  • Cornercap Investment Counsel's Fate Therapeutics position peaked at $322K in Q1 2024.
  • 159 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2024.

Based on Cornercap Investment Counsel's 13F filing for Q4 2024, filed 12 Feb 2025.